ebook Munafa Stock Market Course + Intraday & FNO calls  

       

Arbutus Biopharma (ABUS) Technical (Analysis) Reports Arbutus Biopharma ["Technical Analysis"] Reports -NASDAQ Stock Exchange MunafaSutra.com

Complete & easy to understand technical analysis of Arbutus Biopharma (ABUS)

Technical Analysis Report for NASDAQ stock ABUS Arbutus Biopharma. Dated: 14 Apr 2026 Updated Daily. Stock trades under Health Care Deals in Major Pharmaceuticals in NASDAQ stock exchange

If you are looking for Tomorrow's Movement Predictions for NASDAQ stock ABUS Arbutus Biopharma then click here. or read Experts views on Arbutus Biopharma or Forecast & share price targets of Arbutus Biopharma

Arbutus Biopharma Opened at 4.36 and Closed at: 4.35, which is -0.46% of previous session's close. It moved within a range of 4.32 and 4.45
The session was a Bearish session with an average volume of 1360400, which is -2.31% of previous session's volumes.

    A Golden cross was found 5 days back on short term averages

    Support for tomorrow is 4.27 and resistance for tomorrow is 4.4
    These support and resistance points are valid for the first 5-15 minutes charts

    Above are simple pivot point calculations. For a list of much stronger support and resistance levels click here. These are way more stronger support and resistance levels, and mark trend reversals and are Support & Resistance levels recommended by experts.

    Support for tomorrow's hourly charts is 4.3, 4.24 resistance for tomorrow's hourly charts is 4.43, 4.5

    10 Day SMA for Arbutus Biopharma (ABUS) is 4.4 and stock is trading below these levels. This is not a good sign for its short term trend

    20 Day SMA for Arbutus Biopharma (ABUS) is 4.38 and the stock is trading below these levels. This is not a good sign for its mid term trend

    50 Day SMA for Arbutus Biopharma (ABUS) is 4.35 and the stock is trading above these levels. This is a good sign for its mid to long term trend

    100 Day SMA is 4.41 and the stock is trading below these levels. This is not a good sign for its long term trend

    200 Day SMA Arbutus Biopharma is 4.18 and stock is trading above these levels. This is a good sign for its long term trend

    20 DMA of Arbutus Biopharma is at 4.38 and 200 DMA is at 4.18, while 50 DMA and 100 DMA are at 4.35 and 4.41 respectively

    Arbutus Biopharma (ABUS) moving average of 20 SMA is at 4.38 and 20 EMA is at 4.39

    Arbutus Biopharma (ABUS) moving average of 50 SMA is at 4.35 and 50 EMA is at 4.4

    Arbutus Biopharma (ABUS) moving average of 100 SMA is at 4.41 and 100 EMA is at 4.39

    Arbutus Biopharma (ABUS) moving average of 200 SMA is at 4.18 and 200 EMA is at 4.23

    Arbutus Biopharma has performed better than Addus Homecare in short term. Holding Arbutus Biopharma could be a better choice for now!

    Ligand Pharmaceuticals has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Ligand Pharmaceuticals, about 12.04% more returns!

    Alnylam Pharmaceuticals has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Alnylam Pharmaceuticals, about 6.66% more returns!

    Endra Life has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Endra Life, about 50.53% more returns!

    Natera Inc has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Natera Inc, about 8.81% more returns!

    Arbutus Biopharma has performed better than Novavax Inc in short term. Holding Arbutus Biopharma could be a better choice for now!

    Supernus Pharmaceuticals has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Supernus Pharmaceuticals, about 0.03% more returns!

    Urogen Pharma has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Urogen Pharma, about 13.52% more returns!

    Veracyte Inc has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Veracyte Inc, about 4.42% more returns!

    Arbutus Biopharma has performed better than Viking Therapeutics in short term. Holding Arbutus Biopharma could be a better choice for now!

    Insmed Inc has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Insmed Inc, about 6.32% more returns!

    Ionis Pharmaceuticals has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Ionis Pharmaceuticals, about 6.34% more returns!

    Arbutus Biopharma has performed better than Vertex Pharmaceuticals in short term. Holding Arbutus Biopharma could be a better choice for now!

    Arbutus Biopharma has performed better than Iradimed Corporation in short term. Holding Arbutus Biopharma could be a better choice for now!

    Vtv Therapeutics has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Vtv Therapeutics, about 0.75% more returns!

    Jazz Pharmaceuticals has performed better than Arbutus Biopharma in short term. You could have earned much better returns by investing in Jazz Pharmaceuticals, about 10.69% more returns!

    Arbutus Biopharma Technical analysis of indicators

    Price action analysis of Arbutus Biopharma (ABUS) based on a short term time period is positive, but trend is highly volatile. A longer time period analysis might give a better idea of the trend.

    ADX buy sell signal for Arbutus Biopharma stock for short term is SELL. Signal strength is Weak and stock is losing momentum.

    MACD generated a SELL signal for Arbutus Biopharma in short term and the sell signal is strong.

    Arbutus Biopharma Stock in short term is moving inside a range for now. Please check in a day or two to for a better buy sell signal. Bears are weakening, and bulls are picking up momentum!

    Ichimoku cloud is of green color and prices are in or below the green cloud Prices appear to be coming down

    CCI has generated a buy signal for Arbutus Biopharma in short term but BUY signal is weak.

    RSI is generating a BUY signal in short term and the buying is gaining momentum.

    MRSI is in negative zone. This is the SELL zone

    Stock of Arbutus Biopharma is picking up buying momentum according to indicator.

    Volume based indicators are showing selling momentum.

    Volume Weighted Averaged Price (VWAP) for short term is 4.37 and Arbutus Biopharma ABUS stock is trading below this level. This means that stock is falling with high volumes. VWAP is rising upwards.

    People seem to be coming out and selling the Arbutus Biopharma ABUS stock. Volume based technical analysis of Arbutus Biopharma ABUS stock is negative.

    Arbutus Biopharma Stock is giving positive returns over a short term period. Returns for a longer term period have been negative.

    Force Index is moving in a negative zone, which indicates selling momentum for short term... Selling momentum is getting weaker.

    Tomorrow's Predictions

    You should also read Tomorrow's Movement Predictions for NASDAQ stock ABUS Arbutus Biopharma These predictions are based on various factors, are easy to understand, and upto 75% accurate!

    And ABUS Experts View which covers a lot of information including buying and selling signals

    ABUS future forecast & share price targets

    You can also take a look at the Charts and indicator analysis here Announcements & NEWS by Arbutus Biopharma or View Candle Stick Charts here

    Chart Arbutus Biopharma (ABUS)  Technical (Analysis) Reports Arbutus Biopharma [

    Videos related to: Arbutus Biopharma (ABUS) Technical (Analysis) Reports Arbutus Biopharma ["Technical Analysis"] Reports -NASDAQ Stock Exchange MunafaSutra.com

    Hindi Basics How To Trade In FnO Futures Options Stock Market

    Hindi Video The Truth Of Stock Markets That Everyone Is Hiding From You

    Arbutus Biopharma (ABUS)  Technical (Analysis) Reports Arbutus Biopharma [

     

    Back to top